MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

Armed with positive results in two phase 3 trials, MSD is poised to be the first drugmaker to file for approval of an oral PCSK9 inhibitor for lowering cholesterol. Top-line results from the CORALreef ...

Ukrainian strikes on Russian oil facilities could be a boon for US refiners The recent wave of Ukrainian drone attacks on Russian oil refineries and export facilities could boost global refining ...

New South Wales energy minister Penny Sharpe has announced that Nicholas Rowley has been appointed chair of the NSW Net Zero Commission. OX2 has appointed Matthias Taft as the new CEO, with Paul ...